NASDAQ:MGEN - Miragen Therapeutics, Inc.
$2.73
 $-0.10
-3.53%
4:00PM EDT
2019-04-18
Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., incorporated on December 8, 2010, is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The Company's clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, the Company is involved in discovering and developing a pipeline of pre-clinical product candidates.The Company's pre-clinical product candidates include MRG-107 and MRG-110. As of December 31, 2016, the Company was conducting a Phase I clinical trial of MRG-106 for the treatment of Mycosis Fungoides (MF). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  MGEN     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 81   199. 07   233. 87  
42 stocks rank:  3. 52 K 1. 43 K 1. 06 K
# analyst opinions:  5. 00   14. 48   14. 09  
mean recommendation:  1. 20   2. 09   2. 01  

quick ratio:  9. 36   5. 29   1. 92  
current ratio:  9. 71   5. 64   2. 40  

target price low:  2. 40   84. 50   115. 74  
target price avg:  3. 18   110. 73   137. 39  
target price high:  4. 81   136. 41   157. 80  
1-yr high:  7. 71   114. 11   138. 85  
last close:  2. 73   87. 56   116. 78  
50-day avg:  2. 89   95. 43   123. 53  
200-day avg:  4. 29   94. 13   121. 20  
1-yr low:  2. 32   72. 67   98. 41  
volume:  117. 68 K 2. 43 M 4. 85 M
50-day avg volume:  185. 37 K 2. 72 M 4. 97 M
200-day avg volume:  183. 82 K 2. 90 M 4. 58 M

1-day return:  -3. 53 % -0. 40 % 0. 07 %
this week return:  -7. 77 % -5. 72 % -4. 11 %
12-wk return:  -4. 21 % 1. 78 % -0. 04 %
52-wk return:  -54. 82 % 10. 81 % 14. 09 %

enterprise value (EV):  40. 58 M 51. 19 B 117. 96 B
market cap:  84. 42 M 43. 00 B 104. 52 B
EBITDA:  -32. 80 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -1. 24   4. 34   13. 27  
enterprise/revenue (EV/R):  4. 84   68. 16   13. 68  
total revenue:  8. 39 M 10. 61 B 38. 24 B
total debt:  10. 30 M 12. 22 B 16. 66 B
debt/equity:  20. 06   46. 86   89. 46  
net income (common):  -32. 70 M 2. 20 B 4. 21 B

shares outstanding:  30. 92 M 570. 91 M 1. 24 B
shares:  22. 78 M 571. 02 M 1. 23 B
shares short:  1. 66 M 9. 93 M 16. 79 M
shares short prior month:  1. 37 M 9. 96 M 16. 58 M
short ratio:  10. 23   5. 31   3. 30  
short % of float:  6. 04 % 5. 81 % 2. 61 %
total cash/share:  2. 02   11. 13   9. 30  
total cash:  62. 48 M 6. 70 B 7. 10 B
free cash flow:  -15. 57 M 3. 58 B 4. 74 B
operating cash flow:  -26. 84 M 4. 14 B 6. 32 B

book value:  1. 67   12. 76   26. 84  
price/book:  1. 64   3. 08   -1. 74  
gross profits:  8. 39 M 8. 03 B 34. 77 B
operating margins:  -394. 52 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  -262. 76 % 37. 02 % 55. 68 %

1-yr max volatility:  21. 07 % --- ---
1-yr mean volatility:  -0. 27 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 10   2. 39   4. 08  
forward EPS:  -1. 41   3. 97   7. 14  
P/E:  -2. 47   13. 59   22. 83  
forward P/E:  -2. 10   -20. 05   14. 49  
PE/G:  0. 04   -1. 46   1. 68  
growth:  -60. 10 % 126. 81 % 29. 29 %
earnings high:  -0. 31   1. 02   1. 63  
earnings avg:  -0. 34   0. 76   1. 51  
earnings low:  -0. 38   0. 47   1. 39  
revenue high:  1. 35 M 2. 68 B 10. 71 B
revenue avg:  620. 00 K 2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -34. 86 % -2. 80 % 5. 29 %
return on equity:  -72. 79 % -18. 52 % 7. 38 %
revenue growth:  -60. 10 % 92. 55 % 19. 15 %
revenue/share:  0. 28   13. 27   55. 24  

beta (1yr vs S&P500):  1. 77   1. 24   0. 93  
sharpe (1yr):  -1. 05   0. 29   0. 60  

held % insiders:  10. 65 % 6. 38 % 3. 38 %
held % institutions:  49. 79 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : MGEN
.    + 0.547 =         0.547 :: INITIAL WEIGHT
.   + 36.417 =        36.964 :: spline projection addition
.    x 1.432 =        52.934 :: industry recommendation factor
.     x 3.14 =       166.218 :: symbol recommendation factor
.    x 1.071 =       178.018 :: EV/R factor
.    x 0.997 =       177.398 :: return on assets factor
.    x 0.993 =       176.106 :: return on equity factor
.    x 0.994 =       175.048 :: revenue growth factor
.    x 2.278 =       398.774 :: current ratio factor
.    x 1.058 =       421.955 :: quick ratio factor
.    x 1.048 =       442.098 :: short ratio factor
.    x 2.016 =       891.445 :: price-to-book factor
.    x 1.195 =      1065.271 :: debt-to-equity factor
.    x 2.135 =      2273.877 :: P/E weight
.    x 2.209 =      5022.901 :: PE/G factor
.    x 1.419 =      7128.653 :: beta factor
.    x 0.906 =      6459.724 :: sharpe factor
.    x 0.965 =      6235.134 :: target low factor
.    x 1.136 =      7081.854 :: target mean factor
.    x 1.087 =      7699.486 :: target high factor
.    x 1.312 =     10099.018 :: industry 2-weeks return factor
.    x 0.975 =      9843.083 :: overall "drift" factor
.    x 0.789 =      7769.226 :: largest single-day jump factor
.    x 0.069 =       537.663 :: low price factor
.      x 1.0 =       537.576 :: factor hist industry gain for week 15
.   cubeRoot =         8.131 :: reduced to standardize
.   - 23.331 =         0.809 :: add/subtract for performance
.                      0.809 :: FINAL WEIGHT for NASDAQ:MGEN


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org